Recursion Pharmaceuticals (RXRX) Projected to Release Quarterly Earnings on Tuesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Recursion Pharmaceuticals to announce earnings of ($0.25) per share and revenue of $10.9680 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same period in the previous year, the firm posted ($0.50) earnings per share. The business’s revenue for the quarter was down 56.8% compared to the same quarter last year. On average, analysts expect Recursion Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Stock Down 1.8%

Shares of NASDAQ:RXRX opened at $2.96 on Tuesday. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.57 billion, a P/E ratio of -2.46 and a beta of 1.00. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18. The stock’s fifty day simple moving average is $3.32 and its 200-day simple moving average is $3.55.

Analysts Set New Price Targets

RXRX has been the subject of several analyst reports. Morgan Stanley boosted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.10.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares in the company, valued at $7,789,349.68. The trade was a 1.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the transaction, the director directly owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. This represents a 0.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 131,937 shares of company stock valued at $486,974 over the last quarter. Insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of RXRX. Corient Private Wealth LLC acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $70,000. Invesco Ltd. increased its position in Recursion Pharmaceuticals by 25.8% during the fourth quarter. Invesco Ltd. now owns 526,144 shares of the company’s stock worth $2,152,000 after purchasing an additional 107,979 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in Recursion Pharmaceuticals by 55.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 25,020 shares of the company’s stock worth $100,000 after purchasing an additional 8,935 shares during the last quarter. NewEdge Advisors LLC raised its stake in Recursion Pharmaceuticals by 149.5% during the fourth quarter. NewEdge Advisors LLC now owns 33,757 shares of the company’s stock worth $138,000 after purchasing an additional 20,226 shares during the period. Finally, XTX Topco Ltd raised its stake in Recursion Pharmaceuticals by 104.0% during the fourth quarter. XTX Topco Ltd now owns 47,908 shares of the company’s stock worth $196,000 after purchasing an additional 24,421 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.